Key facts
- Diagonal Therapeutics’s last known valuation is $458.5M (Jan 2026).
- It has raised $271.3M across 2 recorded rounds; the latest was Early Stage VC (Series B) ($125.0M) in Jan 2026.
- Notable investors include Lightspeed Venture Partners, Viking Global Investors, RA Capital Management, Logos Capital, Frazier Healthcare Partners — 17 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Diagonal Therapeutics
Funding rounds
2 roundsAbout Diagonal Therapeutics
Operator of a biotech company intended to discover and develop agonist antibodies. The company's platform combines proprietary computational and experimental techniques to overcome historical challenges associated with agonist antibody drug discovery, enabling medical practitioners to deliver therapies to patients, including therapies for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2022
- Employees
- 28
- Website
- diagonaltx.com/
- Ownership
- Privately Held (backing)
Diagonal Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Diagonal Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Diagonal Therapeutics in its N-PORT filings yet. We sweep new filings monthly.